|MDACC Study No:||2010-0516 (clinicaltrials.gov NCT No: NCT01253460)|
|Title:||A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH|
|Principal Investigator:||William G. Wierda|
|Treatment Agent:||Cyclophosphamide; Rituximab; Sapacitabine|
|Study Description:||The goal of this clinical research study is to learn if sapacitabine given in |
combination with 2 standard drugs (cyclophosphamide and rituximab) can help to
control CLL and SLL. The safety of this drug combination will also be studied.